237 related articles for article (PubMed ID: 3528046)
1. New approaches for the prevention of rejection and graft-vs.-host disease in clinical bone marrow transplantation.
Slavin S; Or R; Naparstek E; Cividalli G; Weshler Z; Weiss L; Mumcuoglu M; Engelhard D; Aker M; Pollack A
Isr J Med Sci; 1986; 22(3-4):264-7. PubMed ID: 3528046
[TBL] [Abstract][Full Text] [Related]
2. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
3. Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow.
Soiffer RJ; Mauch P; Tarbell NJ; Anderson KC; Freedman AS; Rabinowe SN; Takvorian T; Murrey CI; Coral F; Bosserman L
Bone Marrow Transplant; 1991 Jan; 7(1):23-33. PubMed ID: 2043874
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
6. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
7. Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms.
Cobbold SP; Hale G; Clark MR; Waldmann H
Prog Clin Biol Res; 1990; 333():139-51; discussion 152-4. PubMed ID: 2308978
[TBL] [Abstract][Full Text] [Related]
8. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
9. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
[TBL] [Abstract][Full Text] [Related]
10. Antilymphocytic antibodies and marrow transplantation. VII. Two of nine monoclonal anti-Thy-1 antibodies used for pretreatment of donor marrow suppressed graft-versus-host reactions without added complement.
Thierfelder S; Cobbold S; Kummer U; Waldmann H; Schuh R
Exp Hematol; 1985 Oct; 13(9):948-55. PubMed ID: 2864278
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow transplantation in miniature swine. III. Graft-versus-host disease and the effect of T cell depletion of marrow.
Sakamoto K; Sachs DH; Shimada S; Popitz-Bergez FA; Pennington LR; Pescovitz MD; McDonough MA; MacVittie TJ; Katz SI; Gress RE
Transplantation; 1988 May; 45(5):869-75. PubMed ID: 3285532
[TBL] [Abstract][Full Text] [Related]
12. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
[TBL] [Abstract][Full Text] [Related]
13. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants.
Soderling CC; Song CW; Blazar BR; Vallera DA
J Immunol; 1985 Aug; 135(2):941-6. PubMed ID: 3891856
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
15. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?
Har-Noy M; Slavin S
Med Hypotheses; 2008; 70(6):1186-92. PubMed ID: 18054441
[TBL] [Abstract][Full Text] [Related]
16. The use of monoclonal antibodies in graft versus host disease prevention.
Brenner MK; Grob JP; Prentice HG
Haematologia (Budap); 1986; 19(3):167-76. PubMed ID: 3536685
[TBL] [Abstract][Full Text] [Related]
17. Chimerism and tolerance: from freemartin cattle and neonatal mice to humans.
Jankowski RA; Ildstad ST
Hum Immunol; 1997 Feb; 52(2):155-61. PubMed ID: 9077564
[TBL] [Abstract][Full Text] [Related]
18. In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host disease.
Kohler PC; Erickson C; Finlay JL; Trigg ME; Edwards B; Hong R; Hank JA; Billing R; Bozdech M; Sondel PM
Cancer Res; 1986 Oct; 46(10):5413-8. PubMed ID: 3530439
[TBL] [Abstract][Full Text] [Related]
19. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
Johnson BD; Drobyski WR; Truitt RL
Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
[TBL] [Abstract][Full Text] [Related]
20. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
Prigozhina TB; Elkin G; Khitrin S; Slavin S
Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
